Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Stem Cell Umbilical Cord Blood Market Forecast: What Market Value Is Expected By 2030?

The stem cell umbilical cord blood market has experienced strong growth in recent years, increasing from $7.98 billion in 2025 to $9.39 billion in 2026, reflecting a compound annual growth rate (CAGR) of 17.7%. This historical growth has been driven by the rising use of stem cell transplants, the expansion of public cord blood banking networks, advancements in treatments for hematological disorders, greater awareness of stem cell-based therapies, and improvements in neonatal healthcare infrastructure.

Looking ahead, the market is projected to maintain its rapid growth trajectory, reaching $17.83 billion by 2030 at a CAGR of 17.4%. Growth during the forecast period is expected to be supported by increasing demand for personalized regenerative medicine, higher investment in cell therapy research, broader application of treatments for neurological and immune-related disorders, greater adoption of hybrid cord blood banking models, and advances in stem cell expansion technologies. Key trends shaping the market include the growing use of advanced cryopreservation techniques, increased integration of stem cells in regenerative medicine, continued expansion of private cord blood banking services, stronger emphasis on preserving cell quality and viability, and the development of hybrid storage solutions for cord blood.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24715&type=smp

Stem Cell Umbilical Cord Blood Market Growth Factors: Which Forces Are Supporting Market Expansion?

The expanding global birthrate is anticipated to serve as a significant catalyst for the advancement of the stem cell umbilical cord blood market. This demographic trend, signifying the count of live births relative to the population over a defined annual timeframe, is largely attributed to enhanced accessibility and reduced costs associated with fertility interventions, thereby facilitating family planning for a larger demographic. Umbilical cord blood is a rich source of hematopoietic stem cells, which hold substantial therapeutic potential for addressing a spectrum of hematological, immunological, and inherited conditions. Furthermore, these stem cells offer an ideal biological compatibility for the infant and can potentially benefit them, their siblings, or other family members. Illustratively, data from the U.S. Centers for Disease Control and Prevention indicated a rise in American births from 3,596,017 in 2023 to 3,622,673 in 2024, representing a year-over-year increase of 1%, underscoring the burgeoning birth trends that are consequently fueling the expansion of the stem cell umbilical cord blood sector.

Stem Cell Umbilical Cord Blood Market Segment Analysis And Revenue Opportunities

The stem cell umbilical cord blood market covered in this report is segmented –

1) By Product Type: Cord Blood Stem Cells, Cord Tissue Stem Cells

2) By Technology: Cryopreservation, Stem Cell Expansion, Cell Separation

3) By Storage Services: Public Cord Blood Banks, Private Cord Blood Banks, Hybrid Cord Blood Banks

4) By Application: Hematological Disorders, Metabolic Diseases, Immune System Disorders, Neurological Disorders, Other Applications

5) By End-User: Hospitals, Research Institutes, Biotechnology Companies, Other End-Users

Subsegments:

1) By Cord Blood Stem Cells: Hematopoietic Stem Cells, Mesenchymal Stem Cells, Endothelial Progenitor Cells, Regulatory T Cells, Natural Killer Cells, Dendritic Cells

2) By Cord Tissue Stem Cells: Mesenchymal Stem Cells, Epithelial Cells, Fibroblasts, Neural Progenitor Cells

Stem Cell Umbilical Cord Blood Market Industry Trends: What Changes Are Reshaping Demand?

Leading entities within the stem cell umbilical cord blood sector are concentrating their efforts on pioneering novel treatments and securing regulatory endorsements, encompassing applications such as cord blood cell therapy for uncommon inherited conditions, bolstering immune system recovery, and advancing regenerative medicine. Essentially, cord blood cell therapy involves leveraging stem cells sourced from umbilical cord blood to address a range of ailments by restoring or mending compromised blood, immune, and other bodily tissues. Illustratively, in October 2024, StemCyte, a significant biotechnology firm headquartered in the United States, was granted regenerative medicine advanced therapy designation by the U.S. Food and Drug Administration (FDA) for its hematopoietic progenitor cell cord blood therapy (HPC Cord Blood), intended for the management of Long COVID-19 syndrome. This particular therapeutic approach employs stem cells from umbilical cord blood to facilitate tissue repair and mitigate inflammation, demonstrating promise in addressing conditions linked to immune dysfunction and degeneration, thereby presenting a minimally invasive and ethically sound alternative for sophisticated regenerative therapies.

Stem Cell Umbilical Cord Blood Market Leading Players Shaping Industry Direction

Major companies operating in the stem cell umbilical cord blood market are Global Cord Blood Corporation, Vita 34 AG, Cordlife Group Limited, StemLife Berhad, MediPost Co Ltd, Smart Cells International Ltd, StemCyte Inc, Celularity Inc, Next Biosciences Pty Ltd, Esperite NV, Cryo Cell International Inc, FamiCord Group, Cells4Life Group LLP, Cryoviva Biotech Pvt Ltd, Americord Registry LLC, ViaCord LLC, China Cord Blood Corporation, CBR Systems Inc, Cord Blood Registry, LifeCell International Pvt Ltd, CryoSave India Pvt Ltd

Access The Complete Stem Cell Umbilical Cord Blood Market Report:

https://www.thebusinessresearchcompany.com/report/stem-cell-umbilical-cord-blood-global-market-report

Stem Cell Umbilical Cord Blood Market Regional Outlook: Where Are The Largest Opportunities Located?

North Americawas the largest region in the stem cell umbilical cord blood market in 2025. Europeis expected to be the fastest-growing region in the forecast period. The regions covered in the stem cell umbilical cord blood market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model